Ypsomed inks deal to manufacture GLP-1 autoinjectors for Novo Nordisk
Novo Nordisk has spent the last two years scrambling to keep up with skyrocketing demand for its blockbuster GLP-1 drugs, the obesity-focused Wegovy and Type 2 diabetes med Ozempic, forcing it to outsource some production of both the drug and its accompanying syringes and injection devices. As it continues to build out its GLP-1 portfolio, the Danish drugmaker has recruited yet another helping hand.
Joining the assembly line is Ypsomed, which has signed on to manufacture “large quantities of autoinjectors” for Novo, it announced Wednesday.
Ypsomed said in the release that the autoinjectors will be used to deliver 1-milliliter doses of various drugs for metabolic conditions, including new medications currently undergoing clinical trials; the Swiss devicemaker’s head of investor relations, Thomas Kutt, told Reuters that the autoinjectors will specifically be paired with Novo’s “second-generation GLP-1s.”

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!